Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Pacific Biosciences Of California (PACB) Non-Current Deferred Tax Liability (2021 - 2022)

Pacific Biosciences Of California has reported Non-Current Deferred Tax Liability over the past 2 years, most recently at $835000.0 for Q4 2022.

For Q4 2022, Non-Current Deferred Tax Liability changed 0.36% year-over-year to $835000.0; the TTM value through Dec 2022 reached $835000.0, changed 0.36%, while the annual FY2022 figure was $835000.0, 0.36% changed from the prior year.
Non-Current Deferred Tax Liability for Q4 2022 was $835000.0 at Pacific Biosciences Of California, roughly flat from $838000.0 in the prior quarter.
Over five years, Non-Current Deferred Tax Liability peaked at $838000.0 in Q4 2021 and troughed at $835000.0 in Q4 2022.